The Proteome of Primary Prostate Cancer

European Urology

69, 942-952

DOI: 10.1016/j.eururo.2015.10.053

Citation Report

#	Article	IF	Citations
1	Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics. Expert Review of Proteomics, 2016, 13, 593-607.	1.3	12
2	The Perseus computational platform for comprehensive analysis of (prote)omics data. Nature Methods, 2016, 13, 731-740.	9.0	6,181
3	Proteomics provides a prognostic marker. Nature Reviews Urology, 2016, 13, 64-64.	1.9	1
4	Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker. Molecular and Cellular Proteomics, 2017, 16, 998-1008.	2.5	58
5	Methods, Tools and Current Perspectives in Proteogenomics. Molecular and Cellular Proteomics, 2017, 16, 959-981.	2.5	130
6	Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1395-1407.	1.0	21
7	Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. European Urology, 2017, 71, 776-787.	0.9	81
8	Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. Cell Communication and Signaling, 2017, 15, 51.	2.7	29
9	Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer. Frontiers in Oncology, 2017, 7, 267.	1.3	19
10	Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget, 2017, 8, 18497-18512.	0.8	54
11	Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis. Oncotarget, 2017, 8, 92966-92977.	0.8	43
12	Advances in nanotechnology for cancer biomarkers. Nano Today, 2018, 18, 103-123.	6.2	86
13	Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research. Methods in Molecular Biology, 2018, 1711, 133-148.	0.4	389
14	Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases. Neoplasia, 2018, 20, 140-151.	2.3	22
15	Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Review of Proteomics, 2018, 15, 65-79.	1.3	41
16	Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nature Communications, 2018, 9, 1176.	5.8	117
17	Gender proteomics II. Which proteins in sexual organs. Journal of Proteomics, 2018, 178, 18-30.	1.2	5
18	Predictive value of combined analysis of proâ€<scp>NPY</scp> and <scp>ERG</scp> in localized prostate cancer. Apmis, 2018, 126, 804-813.	0.9	12

#	Article	IF	Citations
19	Promise and Implementation of Proteomic Prostate Cancer Biomarkers. Diagnostics, 2018, 8, 57.	1.3	9
20	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Science Alliance, 2018, 1, e201800042.	1.3	51
21	Tissue proteomics studies in the investigation of prostate cancer. Expert Review of Proteomics, 2018, 15, 593-611.	1.3	8
22	The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications. Clinical Cancer Research, 2018, 24, 5433-5444.	3.2	68
23	Recent Advances in Prostate Cancer Treatment and Drug Discovery. International Journal of Molecular Sciences, 2018, 19, 1359.	1.8	183
24	Computational Methods for Understanding Mass Spectrometryâ€"Based Shotgun Proteomics Data. Annual Review of Biomedical Data Science, 2018, 1, 207-234.	2.8	108
25	Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity. International Journal of Molecular Sciences, 2018, 19, 1223.	1.8	24
26	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16987-16996.	3.3	14
27	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel, Switzerland), 2019, 6, 82.	0.7	68
28	Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia. Proteomics, 2019, 19, e1900174.	1.3	27
29	Highâ€throughput proteomic analysis of <scp>FFPE</scp> tissue samples facilitates tumor stratification. Molecular Oncology, 2019, 13, 2305-2328.	2.1	100
30	Integrative proteomic and phosphoproteomic profiling of prostate cell lines. PLoS ONE, 2019, 14, e0224148.	1.1	14
31	Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications. Cancers, 2019, 11, 1729.	1.7	12
32	Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers. Scientific Reports, 2019, 9, 12322.	1.6	26
33	BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. Journal of Cellular Physiology, 2019, 234, 15194-15205.	2.0	32
34	Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. International Journal of Molecular Sciences, 2019, 20, 2626.	1.8	80
35	Update on proteomic studies of formalin-fixed paraffin-embedded tissues. Expert Review of Proteomics, 2019, 16, 513-520.	1.3	18
36	Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. Clinical Proteomics, 2019, 16, 15.	1.1	15

#	Article	IF	Citations
37	The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 2019, 35, 414-427.e6.	7.7	168
38	Drug Repositioning Strategies to Explore New Candidates Treating Prostate Cancer. , 2019, , 801-826.		2
39	Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis. Molecular Cancer Research, 2019, 17, 1166-1179.	1.5	51
40	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology, 2019, 2, 405-412.	2.6	14
41	ETS Rearrangements, Neuroendocrine Modulators, and Androgen Resistance: What Can the Microenvironment Reveal in Prostate Cancer?. European Urology Oncology, 2019, 2, 413-414.	2.6	0
42	High sensitivity proteomics of prostate cancer tissue microarrays to discriminate between healthy and cancerous tissue. Journal of Proteomics, 2019, 197, 82-91.	1.2	18
43	Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells. Clinical Cancer Research, 2019, 25, 2621-2632.	3.2	54
44	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 595-608.	3.2	55
45	Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer. Journal of Proteome Research, 2020, 19, 2631-2642.	1.8	21
46	Landscape of cancer diagnostic biomarkers from specifically expressed genes. Briefings in Bioinformatics, 2020, 21, 2175-2184.	3.2	41
47	Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by antiâ€androgens. Prostate, 2020, 80, 214-224.	1.2	10
48	Proteome dynamics analysis identifies functional roles of SDE2 and hypoxia in DNA damage response in prostate cancer cells. NAR Cancer, 2020, 2, zcaa010.	1.6	7
49	FABP5 as a novel molecular target in prostate cancer. Drug Discovery Today, 2020, 25, 2056-2061.	3.2	38
50	An overview of advances in multi-omics analysis in prostate cancer. Life Sciences, 2020, 260, 118376.	2.0	18
51	Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. Molecular Cancer Research, 2020, 18, 1500-1511.	1.5	13
52	A Novel Nanoproteomic Approach for the Identification of Molecular Targets Associated with Thyroid Tumors. Nanomaterials, 2020, 10, 2370.	1.9	17
53	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics, 2020, 10, 658.	1.3	7
54	The Mitochondrial Proteome of Tumor Cells: A SnapShot on Methodological Approaches and New Biomarkers. Biology, 2020, 9, 479.	1.3	4

#	Article	IF	Citations
55	Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biology, 2020, 21, 302.	3.8	17
56	Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer, 2020, 20, 437.	1.1	44
57	Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clinical Proteomics, 2020, 17, 17.	1.1	165
58	Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by densityâ€based fractionation of urine. Journal of Extracellular Vesicles, 2020, 9, 1736935.	5.5	101
59	Integrative proteomics of prostate cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 43-49.	0.6	0
60	Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer & Metabolism, 2020, 8, 11.	2.4	63
61	Identification of Novel Prognosis and Prediction Markers in Advanced Prostate Cancer Tissues Based on Quantitative Proteomics. Cancer Genomics and Proteomics, 2020, 17, 195-208.	1.0	21
62	The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression. Molecular and Cellular Proteomics, 2021, 20, 100026.	2.5	39
63	Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI. Cancer & Metabolism, 2021, 9, 9.	2.4	62
64	The diversity and breadth of cancer cell fatty acid metabolism. Cancer & Metabolism, 2021, 9, 2.	2.4	107
65	Lipid metabolism part I. , 2021, , 71-135.		0
66	Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis, 2021, 42, 685-693.	1.3	10
67	SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy. Cancers, 2021, 13, 715.	1.7	9
68	TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells. Molecular Cancer Research, 2021, 19, 1113-1122.	1.5	4
69	Dysregulated Free Fatty Acid Receptor 2 Exacerbates Colonic Adenoma Formation in Apc^{Min/+} Mice: Relation to Metabolism and Gut Microbiota Composition. Journal of Cancer Prevention, 2021, 26, 32-40.	0.8	5
70	Benchmarking mass spectrometry based proteomics algorithms using a simulated database. Network Modeling Analysis in Health Informatics and Bioinformatics, 2021, 10, 1.	1.2	0
71	Identification and Characterization of Alternatively Spliced Transcript Isoforms of IRX4 in Prostate Cancer. Genes, 2021, 12, 615.	1.0	4
72	An integrated landscape of protein expression in human cancer. Scientific Data, 2021, 8, 115.	2.4	38

#	Article	IF	Citations
73	Quantitative Proteomics Analysis of FFPE Tumor Samples Reveals the Influences of NET-1 siRNA Nanoparticles and Sonodynamic Therapy on Tetraspanin Protein Involved in HCC. Frontiers in Molecular Biosciences, 2021, 8, 678444.	1.6	7
74	Investigation of Neural Microenvironment in Prostate Cancer in Context of Neural Density, Perineural Invasion, and Neuroendocrine Profile of Tumors. Frontiers in Oncology, 2021, 11, 710899.	1.3	15
75	Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Scientific Reports, 2021, 11, 18936.	1.6	6
76	Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes. Cancers, 2021, 13, 4829.	1.7	9
81	Proteomics and peptidomics: moving toward precision medicine in urological malignancies. Oncotarget, 2016, 7, 52460-52474.	0.8	61
82	Precision Medicine Approach in Prostate Cancer. Current Pharmaceutical Design, 2020, 26, 3783-3798.	0.9	9
83	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. ELife, 2020, 9, .	2.8	104
90	ERG expression in prostate cancer: diagnostic significance and histopathological correlations. Egyptian Journal of Pathology, 2020, 40, 212.	0.0	0
92	CHAPTER 10. Applications for Mass Spectrometry-based Proteomics and Phosphoproteomics in Precision Medicine. RSC Detection Science, 2020, , 191-222.	0.0	0
93	Prostate cancer between prognosis and adequate/proper therapy. Journal of Medicine and Life, 2017, 10, 5-12.	0.4	51
94	Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. Cancers, 2021, 13, 6036.	1.7	7
95	Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites, 2021, 11, 765.	1.3	21
96	Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification. Journal of Translational Medicine, 2022, 20, 18.	1.8	4
97	Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics. Cancers, 2022, 14, 1702.	1.7	13
98	Muscle wasting assessment tools for prostate cancer. Scientific Reports, 2022, 12, 4662.	1.6	0
99	On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances. International Journal of Molecular Sciences, 2021, 22, 13537.	1.8	11
100	2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Ameliorates Diabetic Cognitive Impairment Through Inhibiting Hif3Î± and Apoptosis. Frontiers in Pharmacology, 2021, 12, 708141.	1.6	2
101	Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies. International Journal of Molecular Sciences, 2021, 22, 13605.	1.8	3

#	Article	IF	Citations
103	Automated quantitative high-throughput multiplex immunofluorescence pipeline to evaluate OXPHOS defects in formalin-fixed human prostate tissue. Scientific Reports, 2022, 12, 6660.	1.6	2
104	Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.. American Journal of Cancer Research, 2022, 12, 1323-1336.	1.4	0
105	Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.. American Journal of Cancer Research, 2022, 12, 1824-1842.	1.4	0
106	Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness. Cancers, 2022, 14, 3765.	1.7	6
107	dbPepVar: A Novel Cancer Proteogenomics Database. IEEE Access, 2022, 10, 90982-90994.	2.6	2
108	Proteomics reveals MRPL4 as a highâ€risk factor and a potential diagnostic biomarker for prostate cancer. Proteomics, 2022, 22, .	1.3	2
110	Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine. Diagnostics, 2022, 12, 3184.	1.3	2
111	Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5803-5822.	1.2	4
112	Proteotranscriptomic Discrimination of Tumor and Normal Tissues in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 4488.	1.8	0
113	Proteomic profiling and its applications in cancer research. , 2023, , 121-153.		0